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AN ANALOGYs INTERFERON AND ENDOGENOUS PYROGEN
Introduction

For a number of years it has been observed that host resistance
to the effects of viral infections could be enhanced by gram negative
bacteria and their products9

42

particularly endotoxins*

(Sidotoxins

are high molecular weight lipopolysaccharides derived from virtually
all gram negative bacteria*

Their exact structure and the factors re-

sponsible for their extraordinary toxicity remain unidentified.^)
» 55
Specifically, Groupe in 1956 demonstrated that xerosin, an endotoxin*®
like material from Achromobacter xerosis, could suppress the neurotoxic
effect of influenza virus in mice when given intracerebrally before,
but not after, inoculation of virus by the same route.

Gledhill re¬

ported that serum of mice treated with endotoxin present in growth
filtrates of Salmonella typhimurium when inoculated into suckling
mice increased resistance to ectromelia virus infection*

49

He also

demonstrated similar effects with saccharated iron oxide and concluded
that stimulation of the reticuloendothelial system was the mechanism
48
involved*

Also, Wagner et® al• were able to increase resistance of

mice to eastern equine encephalitis and encephal©myocarditis viruses
by administration of endotoxin®

155

More recently, there have appeared in the literature suggestions
that the *’hon»specificM enhanced resistance to virus infections caused
by bacterial endotoxins might be due to the production of the low
molecular weight protein moiety called interferon.

Indeed, Stinebring

2

and Youngner

1

and Ho

reported that bacterial

endotoxins do,

in fact, induce the release of an interferon-like material in vivo
in chickens, mice and rabbits#
It has been known for some time that one of the most sensitive
indices of endotoxin activity is its pyrogenic effect in laboratory
animals,®^

As little as 0*0001|jg per kilogram is capable of producing

a detectable pyrogenic response in the rabbit.

90

The mechanism by which

endotoxins cause fever has been attributed to the release into the
circulation of an endogenous pyrogen,

9 1 25
* '
which can be differentiated

from endotoxin and will cause a fever when injected into a recipient
animal«
Thus, because of these observations, viz, that endotoxins induce
release of both endogenous pyrogen and interferon, it was the proposal
of this thesis to investigate a possible relationship between these
two entities using a single inducer-host system.

-3

Interferon? A Review
Although the phenomenon of viral interference had been, upto
that time., demonstrated by several investigatorsf4*^91^

nrior

to 1957, no one Identified an active interfering principle distinct
from virus material itself or from part of the host’s immunologic
response#

It remained for Isaacs and Lindenmarm to achieve some

preliminary characterization of such a substance? they called it
wthe interferon.w^Using heat-inactivated influenza virus and
fragments of chick chorio-allantoic membrane, they found a soluble
factor was released that induced interference in fresh pieces of
chorio-allantoic membrane.

Until this time, all Interference had

been considered to be a direct effect of whole interfering virus or
of virus components®''’''

The interferon of Isaacs and Lindenmarm was

stable in the cold but inactivated at 60°C for 1 hour.

It was not

dialyzabie nor was it sedimented by 100,000 g for ■§- hour.

Interferon

produced in response to influenza A was active against homologous
virus, Sendai, Newcastle Disease and vaccinia viruses.

It was not

neutralized by specific anti-serum and did not agglutinate red blood
cells.

Their astute initial observations have lead to a whole new

field of research and a voluminous literature concerning this sub¬
stance that, it is hoped, might curtail a wide range of virus infections.
Definition?
There has been considerable difficulty in defining exactly what
interferon is? one must resort to listing a number of characteristics

4
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which must be met before identifying a substance as interferon.
These may include its source and inducing agent, its mechanism of action
and its physico-chemical properties.

In general, interferon is the

name given to a group of anti-viral proteins produced by vertebrate
cells in response to a number of inducing agents, including many viruses*
It is distinct from virus material and confers resistance against
multiplication of viruses in homologous cells®

77

As will be elucidated

later, there have been a number of species of interferons released by
various inducing agents and these differ somewhat in their properties.
It has been suggested, therefore, that interference be looked upon as
a cellular function, rather than as an isolated biochemical phenomenon®
The remainder of this section will be devoted to a review of the present
knowledge on the identity of interferon.
Assay Techniques?
To date there is no biochemical or immunologic assay for interferon®
However, there have been a number of different interferon bio-assays
developed.

The type most widely used measures the degree of inhibition

of virus production by cells treated with the interferon preparation
before infection®

In general, this can be measured bys(l) a decrease

in the yield of virus from the treated cells? or (2) the decreased
susceptibility of the infected cells to a virus lesion (e.g., a plaque
or cytopathogenic effect).

Originally, Isaacs and Lindenmarm measured

the effect of interferon by reduction of influenza virus hemagglutinin
titer®®^

This type of assay has largely been replaced by the more

-5-

sensitive plaque reduction assay in which the concentration of
interferon that will reduce the plaque count by 50% in a tissue
culture monolayer is measured#

*'

In this system a linear

relationship exists between the percentage of plaque reduction and the
log of the interferon concentration; therefore, it is legitimate to
determine the end point of the assay by interpolation.

Although

this technique is not as sensitive as some, it has been used widely
because of its relative simplicity and reproducibility#
h

assay technique used by nitchcock
cup technique.

63

137

Another

is an adaptation of the Oxford

Its principle is that the size of a zone of protection

afforded by interferon allowed to diffuse through agar over a sheet
of virus-infected cells is directly proportional to the concentration
of interferon#

This technique is not widely used#

A fourth technique described by Sellers and Fitzpatrick

135

is

based upon the degree to which cell cultures are protected against
cytopathogenic effect as evaluated microscopicp11y#

All these

techniques are well reviewed in ’’Techniques in Experimental Virology"
(R.J.C. Harris, ed.)*27
Interferon-Producing Systems*
Soon after interferon production was described in chick cells
infected with inactivated influenza virus, many other inducer-cell
systems were shown to produce interferon.
Ho listed almost 35 dif77
ferent systems in 1962;
their range is extremely wide and has been
constantly expanding.

Most of these systems employ in vitro cell

62 6'
cultures; however, many in vivo models have also been described#'”'*"’

•*r
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Viruses as inducers?

Viruses demonstrated to induce production

of interferon include both RE and DM viruses, a wide range of sizes
and both cytolytic and tumor viruses.

One may justifiably conclude,

then, that the production of interferon is a rather general response
of cells to virus infection.
The viruses used as interferon inducers include members of the
myxovirus,

arbovirus,

*

polyoma,

measles,

enterovirus,'"* vesicular stomatitis/^ foot-and-mouth disease,'"' and
vaccinia virus groups.

47

An equally impressive number of viruses have

been shown to be inhibited by interferon and it seems quite likely that
i 50
no virus will be found to be completely unaffected.""
may be the adenoviruses.'0 )

(An exception

Two essential properties of virus-induced

interferons are worth noting? (1) interferons induced by different
viruses in a single cell system seem to be identical as far as can be
determined; and (2) interferons induced by different viruses in a single
cell system show no evidence of virus specificity, i.e., they are not
most active when tested against the homologous virus.

150

Much has been written about the relative effectiveness of the
various inducers of interferon.

In addition to cell type and environ¬

mental factors, titers of interferon are influenced by the inf activity,
dose, strain and virulence of the inducing virus*

The difference in the

relative ability of inactivated and virulent viruses to induce interferon
is not understood.

The original studies

showed that UV-i motivated

influenza virus is a better stimulator of interferon production than
heat-inactivated or fully infectious virus*

Although there is a lack

-7-

of entirely adequate quantitative data, there is suggestive evidence
that infectious avirulent viruses stimulate cells to produce more
150
interferon than do virulent strains®

Ho and gliders, in 1959,

showed that the attenuated strain of poliovirus is a good interferon
inducer®

Vaccine strains of Newcastle Disease virus are relatively

poor interferon inducers in chick embryo cells, although they are
more efficient than the virulent variants®

132

Enders states that

attenuated measles virus is a better interferon inducer than the
virulent strains#

36

In distinct contrast to the myxoviruses, inactivated arboviruses
and enteroviruses are notoriously poor inducers? whereas, under the
69,146
same conditions the identical infectious viruses elicit a good response®
Ho and Breinig

68

reported that heat-inactivated Sindbis virus induced no

interferon production tout “sensitized** cells released greater amounts of
interferon when challenged with infectious virus.

One explanation

offered is that inactivated virus initiates the production of an income
plete interferon, the synthesis and release of which may be affected by
the addition of active virus*

77

It would thus seem that the capacity to induce interferon production
is, at least in part, a property of the virus®
studies of Thiry

143

This is supported by the

who showed that one characteristic of chemically in¬

duced mutant strains of NDV is the capacity to induce higher yields of
interferon per infectious particle®
In addition to the differences in the amount of interferon which
viruses can induce, they also differ in their sensitivity to the antiviral

-8

action of interferon#

(it is not known if these two properties,

which may help to determine virus virulence, are in any way related#)
As an example, Ruiz-Goxnez and Isaacs

showed that NDV plaque re¬

duction required almost 30 times more interferon than an equivalent
inhibition of 0’nyong-nyong virus#

Also, Herpes simplex virus is

much more resistant to the action of interferon than vaccinia or
cow pox viruses grown on chick chorion#

80

Viruses which in general

are relatively resistant to interferon action include fowl plague,
NDV, Herpes simplex, pseudorabies

and adenoviruses#

(It is inter¬

esting to note that some members of this resistant group, especially
Herpes and adenoviruses have been associated with long-term chronic
infections in man#)

Vaccinia, many arboviruses and rhinoviruses

14 139
seem to be relatively more sensitive#" *
Non-viral inducers of interferons

A variety of non-viral materials

have been reported to be effective inducers of interferon in both in
vivo and in vitro systems#

These include heterologous animal nucleic

78 1
72
161
88
acids, 0,101 rickettsiae,
bacteria,
yeasts,
statolon ( a poly95
saccharide derived from Penicillium stolonif erium),
helienine (an
133
antibiotic-like material from Penicillium funiculosum),~ ~ cyclohexamide.

X 02

13

irp

Mycoplasma,10 phytohemagglutinin,J OD and, of course,

endotoxins #^8

It has been theorized that many materials like statolon

and helienine may be effective as inducers because they, like nucleic
acids, are polyanionic macromolecules#

95

Some of these systems are certainly radically different from the
classic virus-cell system and are in general a testament to interferon

-9-

production being a more general host response to insult®

Isaacs

drew the analogy that antibody production is a response to a
foreign protein, whereas interferon production may be a response
to foreign nucleic acids at the cellular level®
Cells involved in interferon production:

81

In vitro, cells from

a wide variety of animal species have been shown to produce interferon;
these include chickens, ducks, mice, rats, guinea pigs, hamsters, rabbits,
ferrets, dogs, sheep, pigs, cows, monkeys and man®

There have been

essentially no differences noted to date in fibroblastic, leukocytic
and epitheloid lines with regard to interferon production or suscept*
ibility®

In vivo production has not been so extensively studied and

there is no indication that any specific organ acts as a site for
interferon production®
It is generally felt that primary and secondary cell cultures are
superior to continuous replicating cell lines for use in interferon
assay systems®^®

The tumor cell lines have been thought to be

rather ineffectual producers of interferon, 1 but this may be due to
the fact that many of these lines are relatively insensitive even to
the interferon produced in the same cells.

Ho and Enders

noted

that interferon produced in HeLa cell cultures infected with attenuated
Type 2 poliovirus worked well in primary human amnion or human kidney
cell cultures but not in infected HeLa cells®
reported by Chang in KB cells

2p

Similar findings were

and for a human amnion cell line by

MayerHowever, that the cell susceptibility may be only relative
in these continuous lines was pointed out by Centell

in showing that

10'

-

HeLa cells did show some sensitivity to the action of homologous
interferon, although less than that of primary human thyroid cells.
Q C

These observations led Isaacs et« al.

to speculate that this be¬

havior might reflect general differences in metabolism between tumor
and normal cells a
Effect of interferon on cells:

The effect of interferon on

tissue culture cells has been actively investigated in attempt to
elucidate the mechanism of action:
(1) Morphological changes: With most tissue culture systems
there has not been observed any significant morphologic change in
interfcron-treated cells®

Wagner and Levy^^ found that Eastern

equine encephalitis virus-infected chick embryo fibroblasts treated
with interferon had normal architecture and nucleic acid distribution®
Pretreated cells were seen to undergo apparently normal cell divisions®
The only morphologic changes described are in cultures of human amnion
cells®^

Between 48 and 72 hours after treatment with interferon the

polygonal cells became fibroblastic in shape®

The cells readily re¬

verted to the original epithelioid type after the interferon-containing
medium was removed®

The same stimulus produced no change in primary

human kidney cells or in continuous cell lines derived from human amnion
cells *
(2) Growth rate changes: Baron and Isaacs11" found that cultures of
primary human thyroid cells subject to one hundred 50^ inhibitory doses
of interferon resisted multiplication of vaccinia virus and continued to

11-

-

grow and divide normally.

They formed confluent monolayers at about

the same time as untreated cultures.

122
Paucker _et. a_l.,
however,

reported that treated L cells in suspension did show some growth retardation when exposed to very high titers of interferon.

The signif-

icance of the contradictory information is not apparent.
(3) Biochemical effects: The work of Levy et.

lends

weight to the data that suggest that interferon has little effect on
uninfected cells.

They found no alteration in the incorporation of

labeled precursors into cellular proteins, phospholipid, nucleotides
or nucleic acids®
Properties of Interferon
Biological Properties:'
Species specificity-Tyrrell in 1959

1 44

first observed that calf

and chick interferons were relatively species specific in that they
were much more active in cell cultures of the homologous species.
Later the specificity was described between chick and rabbit cells® 1
and even for duck and chick cells.

Merigan,

using a highly

purified preparation, has demonstrated that interferon produced in
mouse tissue does not inhibit the replication of interferon-sensitive
viruses in chick embryo cells and, conversely, that chick interferon is
not active in mouse cultures®

However, a number of workers have stated

that this specificity may not be quite so absolute®

Sutton and Tyrrell

reported on their work showing that monkey interferon was active in
human and calf tissue, although calf interferon failed to manifest any
activity in monkey kidney cells.

Curiously enough. Sellers and

1

12-

•

Fitzpa trick found just the opposite one-way relationship between
calf and monkey interferons a135

Some more recent studies have

demonstrated that mouse interferon exhibits about

of its anti¬

viral activity on phylogenetically related rat embryo and hamster embryo
cells but none on distantly related monkey testis or chick embryo
cells.22

The data of Paucker121 seem to have contributed considerably

in resolving the conflict.

He reported that interferon activity in

heterologous cells was reduced to about 3% of that in homologous
systems and that this same fraction of interferon-like activity was
not neutralized by anti-interferon antibody.

Of course, this raises

the question of the variability of specificity of interferons with
the degree of purification of the preparation.

His data suggest that

this anti-viral activity in heterologous species may be attributable
to viral inhibitors other than interferon*

When the most purified

interferons available at this time are used, a strong species specificity has been demonstrated.

103

Antigenicity-Interferon is quite distinct as an antigen from the
virus that induces its production.

85

Several groups of investigators

have found interferon to be a rather poor antigen, however.

When

inoculated into rabbits or chickens either alone or with oil adjuvants
or after alum precipitation, chick interferon did not induce the pro1 I c

duction of interferon-neutralizing antibody."

Nagano and Kojima

found that a series of injections of rabbit interferon into hens,
guinea pigs and two groups of rabbits produced no neutralizing antibody?
however, a third group of rabbits developed antibodies as measured in

13-

rabbit skin.

They later confirmed the positive observation and also

found neutralizing: substances in the serum of immunized, fowl,
Furthermore, Paucker and Cantell

1 23

119

have found that after prolonged

immunization of guinea pigs with mouse interferon a low titer of
antibody was produced®

It could be demonstrated only by using very

dilute preparations of interferon®
Glasgow

does not find it surprising that interferon is a poor

antigen and likens it to the polypeptide insulin.

Insulins produced

in different species vary by only a few ami.no acids and as a result
are poor antigens when injected into heterologous species.

Interferons*

too, may vary only slightly in their structure and fail t© be recog¬
nized as foreign proteins by a host.
Physico-chemical properties?
O K

Interferon is a non-dialyzable and non-sedimentable protein.
Purified preparations have been found to contain no nucleic acid and
only a trace of carbohydrate.

148

The protein, glycoprotein or poly¬

peptide nature of interferon is inferred primarily from the fact that
its antiviral activity is greatly reduced or abolished by treatment
with proteolytic enzymes such as trypsin, pepsin or chymotrypsin.^9®8»148
On the other hand, it is not affected by treatment with ribonuclease,
desoxyribonuclease or neuraminidase.

Its ultraviolet adsorption

spectrum is characteristic of a protein, i,e», maximum absorption at
about 280mp*
It is stable over a wide range of pH (from pH 2-10) j

this

property has been used to great advantage in eliminating infectious

14-

-

virus particles from interferon preparations®

The protein has been

characterized as slightly basic with an isoelectric point at about
pH 8®Q#^^

It is precipitated in the 60% saturated ammonium sulfate

fraction^"0® and by acetone or ethanol® ®9^ ^

Glasgow and Habel^

reported that their mouse embryo interferon was inactivated by ether
but Chany^® observed no effect when an interferon preparation derived
from KB cells infected with parainfluenza virus was ether-treated.
Generally the interferons have been found to be thermostable;
some of the conflicting reports, however, may be due to pH differences
and the stabilizing effects of other proteins in crude suspensions®
It is stable on storage at -2°C, *XQ°C and -7G°C; and most workers
have found only partial loss of activity at 56°C for 30 minutes*®®
Antiviral activity is lost when preparations are heated at 76°C for
1 hour.

Although species differences in heat stability do exist,

Chany found that his preparations of human interferon were entirely
0

inactivated after heating at 56 C for 30 minutes®

Merigan showed

that the heat inactivation curve of his highly purified mouse inter¬
feron was significantly different from similar preparations of chick
cell interferon.^-^
The molecular weight of interferon has been a much-investigated
Q £?

topic®

In 1963, Lamp son et® al *

studied a highly purified prepar¬

ation of chick interferon and estimated, by means of high-speed
centrifugation, that it had a molecular weight of 20,000-34,000#
Rotem and Charlwood

carried out studies of the molecular weight

of chicken, mouse and monkey interferons by means of sedimentation in

-15

sucrose density gradients along with radioactive markers of known
molecular weight*

They found each to have a molecular weight close

to that of lysozyme with limits of 13,000-25,000*
With the discovery of non-viral inducers of interferon, it was
found that some of the materials meeting the standard criteria had a
Q7 113 114 160
wide range of molecular weights from 20,000 to 100,000*"' 9 " ' 9 '
At first it was thought that viruses induced the 30,000 MW interferon
and that non-viral inducers, such as endotoxin, led to the release of
a high molecular weight preformed interferon*

However, statolon in¬

duces the synthesis of a 30,000 MW interferon in tissue culture,*
and the release of a heavy species molecule into the circulation of
animals.1"

Additional findings are that the spleens of mice treated

with statolon contain a 30,000 MW interferon and phytohemagglutinin
1 %

induces the formation in white blood cells of an 18,000 MW variety*
Youngner, Hallum and Stinebring prepared the following list of
interferon molecular weights obtained by intravenous injection of the
various inducing agents into mice:
Stimulus

Viruses t
NDV
Bacteria & products:
Brucella abortus
E.coli endotoxin
Mold products:
Statolon (Penicillium)
Cyclohexamid e
(Streptomyces)

Molecular Weight by Sephadex
G-100 gel Filtration

25,000
77,000
54,000
89,000
90,000
41,000

♦Only light interferons have been detected in tissue culture so far.,

■16

It would seem., then, that a wide range of molecular sizes can be
recovered from animals in response to various stimuli*

It is not

known whether the interferons of different molecular weights may be
related to each other in the sense of polymers of some subunit or by
having an active moiety attached to different protein carriers*
It has been observed that endotoxin-induced release of high
molecular weight interferon into the serum is not inhibited in mice
treated with cyclohexamide to inhibit protein synthesis*

The

same results have been obtained in rabbits treated, with inhibitors of
RM and protein synthesis?
used as the inducing agent*

whereas, it is inhibited when virus is
It would seem reasonable to conclude,

therefore, that endotoxin-induced interferon is probably not produced
in the same way as virus-induced interferon, i.e®, that endotoxininterferon does not require the synthesis of a new messenger RM or
protein*

These results have been interpreted as indicating that the

interferon released in animals upon treatment with endotoxin is not
newly-formed, but rather preformed in some cells, perhaps the reticulo¬
endothelial system*

Mechanism of Actions
A number of observations about the action of interferon were made
quite soon after its discovery*^’9 J

Ho and Enders,"^ Isaacs and

Burke,Vilcek,^® and Wagner,-^9 all demonstrated quite conclusively
that it did not act directly on the virus*

Grossberg and Holland01"

failed to detect any evidence of a block in release of newly synthesized

17-

particles in poliovirus-infected cells treated with interferon.
These data, along with evidence from Isaacs”

work26*'80 that there

was no accumulation of synthesized but unassembled viral components,
strongly implied that the assembly and release phases of virus multi®
plication were unaffected.

Moreover, it has been demonstrated that

interferon forms a stable complex with cells which cannot be dissociated by washing or even disrupting the cells.

This means

that interferon must be fixed to and perhaps even metabolized by the
cell as a prerequisite to its antiviral action.

Therefore, attention

was focused on the more challenging processes involved in the intra¬
cellular synthesis of viral protein and nucleic acid.
One of the first suggestions concerning the mode of action was
that interferon-treated cell cultures showed increased glycolysis,
increased lactic acid production and increased oxygen consumption.
These observations are similar to those made of cell cultures exposed
to dinitrophenol which inhibits or uncouples oxidative phosphorylation.
These presumed effects were found to be due to impurities in the crude
preparations of interferon, as there was no evidence for this when the
experiments were done with purified interferon.1
the hypothesis was offered by Zemla and Schramek,

Other evidence against
1 6^

who were able to

show that interferon inhibits the replication of western equine en¬
cephalitis virus under anaerobic conditions.

Since oxidative phosphor¬

ylation does not occur without oxygen, it is unlikely that uncoupling
could be the mechanism.

More evidence bep-an to accumulate about the precise site of
interferon action,

DeSomer34 demonstrated that interferon inhib-

ited the synthesis of viral RM and also Grossberg and Holland,

54

Ho,'®® and Mayer et.al.^® proved that this inhibition was exerted
on infectious viral RM as well as on whole virus.

These data con¬

firmed earlier impressions that interferon acts intr&celluiarly and
more specifically on the synthesis of -viral nucleic acids and protein.
An interesting observation made by Houo is that over a narrow
dosage range the inhibitor of virus plaque formation conforms to
first-order kinetics.

This has been interpreted as implying that

perhaps as little as one molecule of interferon is sufficient to
render one cell resistant to virus infection.
A series of experiments described by Taylor in 1964^4^
added much to the attempt to further define the mode of action.
She took advantage of the fact that the antibiotic actinomycin D
inhibits DNA-dependent RM synthesis without affecting viral RM
synthesis in cells infected with Semliki Forest Disease virus.
In the absence of interferon, actinomycin-treated and infected
cells incorporated tritium-labeled adenosine into viral RM. and
the virus multiplied normally.

When cells were first treated with

partially purified interferon for 5 hours and then treated with
actinomycin D overnight and infected with virus, the synthesis of
viral RM and the yield of progeny were markedly reduced.

However,

if the cells were treated with actinomycin before they were exposed
to interferon, viral RM synthesis and viral replication were not

**19

inhibited by interferon#

These data have been construed as evidence

that interferon acts by inducing cellular synthesis of a new messenger
M which, in turn, presumably codes for the synthesis of a new cell®
ular protein*

It would seem that this interferon-induced protein

appears to be the active component in this inhibition of viral RN&
synthesis*
These results have been confirmed by Lockhart-*-06 who als©
demonstrated that actinomycin can reverse the antiviral action of
interferon for a period of 2 to 3 hours after exposure*

Additional

weight has been lent to these theories by reports that selective in¬
hibitors of protein synthesis, p-fluorophenylalanine4'''’ and puromycin1,01
also block interferon action*

Thus far, no one has isolated the

interferon-induced protein that inhibits viral RNA synthesis but
the evidence for its existence seems conclusive*
Very recently, Marcus and Salb-*-u^ have published evidence further
elucidating the precise site of interferon action*

The authors used

a cell-free protein synthesizing system, with Sindbis virus RNA as
messenger and ribosomes from normal and interferon-treated chick
embryo cells.

Using polyribosome, breakdown (as evidenced by loss

or ribosomai RNA absorbancy and labeled viral RNA from the 250 $
region) as evidence of messenger RNA readout and protein synthesis in
normal and interferon-treated cells, they showed that interferon inhibits
virus messenger RNA translation, while messenger from the cell genome
is translated normally*

They therefore postulate that the inhibition
8

of viral RNA translation constitutes the primary mechanism of action of

SO”

viral interference.
Thus it can be seen that although much about interferon
remains to be learned, a tremendous amount of information has
been accumulated with ten short years of its recognition*

21-
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ENDOGENOUS PYROGEN

Introduction
Fever is one of the most common signs of illness , but until quite
recently little has been understood about its pathogenesis*

In the

mid-nineteenth century pyrogenic agents were found in pus and necrotizing tissues.

1 Q

Later, Hort and Penfold, while studying

"injection fevers" found that the pyrogenic agents were in fact
bacterial cell contaminants*

The most potent of these pyrogens

were shown to be soluble materials associated with gram negative
bacteriaand for some time it was taken for granted that most
clinical fevers were directly related to these pyrogens*

The

concept of pyrogens of endogenous origin was reintroduced by Menkin
who found a "pyrexin" in inflammatory exudatesHowever,
his material was later shown to have characteristics identical with
bacterial endotoxin and probably was due to gram negative bacterial
endotoxin contamination*
The existence of a pyrogen truly endogenous to an animal was
first demonstrated by Beeson^0 in polymorphonuclear leukocytes ob¬
tained from sterile saline-induced peritoneal exudates*

The cells

were lysed by shaking with glass beads and the supernatants were
shown to be pyrogenic when injected intravenously into rabbits*
This pyrogen was clearly different from endotoxin in its heat
lability, rapidity of action and the absence of tolerance to re¬
peated injection.

However, in screening other rabbit tissues.
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Bennett and Beeson^ were unable to find evidence of pyrogen
except in those containing large numbers of leukocytes.
Much of the experimental fever work has been done with gram
negative bacterial endotoxins, lipopolysaccharides of about one
QQ

million molecular weight.

It has been quite well demonstrated

that the pyrogenic effects of endotoxins are mediated in large
part through the release of an endogenous pyrogen, presumably from
circulating granulocytes.

17

The release of this pyrogenic substance

has also been demonstrated in vitro.
Endotoxins when given intravenously characteristically induce
a fever with a latent period of 20-30 minutes.

158 IgQ
*

When suf¬

ficient endotoxin is given, the response is a biphasie fever with
peaks at one and three hours.0®

The response of circulating leuko¬

cytes varies with the dose of endotoxins small doses evoke no change
or only a progressive leukocytosis without an initial leukopenia;
larger doses, however, cause an initial leukopenia during the
Q
latency period, followed by a leukocytosis.
Several other experimental fever systems have been shown to
involve the release of an endogenous pyrogen:
(l) Gram positive bacteria do not possess the Xipopolysaceharide
endotoxins that are found in virtually all

gram negative organisms

It was thought from very early experiments that gram positive bacteria
were not immediately pyrogenic when given intravenously.

A fever

appeared only after several hours delay when an infection was established®

74

This was shown not to be the case, however, by Atkins and
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Freedman in 1963*

Large numbers of autoclaved gram positive

organisms given intravenously caused biphasic fevers after a
latent period of 45-60 minutes*

This delay period is signif¬

icantly longer than that for endotoxins given by the same route*
Streptococci have also been shown to contain several non-infectious
pyrogenic material s*^9^^
It should be pointed out that intravenous injection of a
number of relatively inert materials also have produced fever
with many of the characteristics of gram positive bacteria*
These include dextran, methyl cellulose, calcium phosphate,

0
sulfur, kaolin, quartz, thorium dioxide, iron oxide and gold*'
(2) Viruses have been shown to produce fever in rabbits
Q 151
when injected intravenously* '9

The fever associated with

virus is somewhat different from endotoxin and gram positive
bacteria-induced fever*

It has a latent period of between

one and two hours rather than 20-30 minutes9 9

1 R]

1 and is asCO

sociated with a lymphopenia rather than a granulocytic response.
The pyrogenic property of the myxoviruses is abolished by incu¬
bation with specific immune seruni,^^^ whereas homologous antibody
does not affect endotoxin5 s ability to produce a fever.

It seems

probable, then, that the initial mechanism of fever production by
virus differs in some basic way from endotoxin fever.
Several investigators have shown that the mediator of virusinduced fever is a pyrogen with the characteristics of the leukocytic
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and endogenous pyrogens associated with other systems®

6 93

Recently Atkins et® al®ij have demonstrated that a myxovirus
can cause release of an endogenous pyrogen when mixed in
vitro 'with whole rabbit blood®

Rabbit alveolar macrophages

have also been shown to release pyrogen in response to whole
virus and to a polysaccharide extract of the virus®

3

Although

a relatively few viruses have been tested for pyrogenicity»
Coxsackie virus has been the only one beside the myxovirus group
to induc e f ev er «9^

^

(3) Another experimental fever system shown to involve the
release of endogenous pyrogen encompasses several immunologic
mechanisms®

Farr et®

*>39,40

used repeated intravenous

injections of bovine serum albumin to sensitize rabbits to
respond with a fever to subsequent challenge with the protein®
The febrile response 'was biphasic and accompanied by leukopenia
but differed from endotoxin fever in its longer latency period®
Circulating antibodies were shown to be involved in the release
of the endogenous pyrogen by passive transfer experiments.

Lymph¬

ocytes transferred from sensitized to normal animals did not mediate
the response®9 ^

It is probably a fair conclusion that an antigen-

antibody reaction causes host cells to release endogenous pyrogen
into the blood stream®
Delayed hypersensitivity has also been shown, to be a mechanism
that releases endogenous pyrogen®

Rabbits which have been infected
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■with BCG vaccine have significant febrile reactions to intracry

venous injections of old tuberculin*1"''

The reaction involves

an early granulocytopenia followed by a prolonged lymphopenia
which is a characteristic reaction of delayed hypersensitivity.'''
This type of fever is distinguished from endotoxin fever by its
latency of nearly one hour.

Atkins and Heijn^ further demon¬

strated that tuberculin releases endogenous pyrogen in vitro
from blood leukocytes of sensitized rabbits, but not from lymph
node and spleen cells.

Since normal blood cells, incubated in

plasma of sensitized donors, were also activated, it was post¬
ulated that circulating antibodies sensitize cells (presumably
granulocytes) to release endogenous pyrogen on contact with
tuberculin.
Fevers have also been shown to be produced with products of
other microorganisms®

Culture filtrates of Staphylococcus aureus

g

21
and of several of the pathogenic fungi “ have been shown to induce
febrile resnonses in nornal rabbits,

Atkins postulates that these

responses are due to sensitization by undetec ted previous infections
of the Hnormal*' animals by homologous or cross-reacting organisms.
Bod el and Atkins

showed that this phenomenon can be passively

transferred with lymphocytes but not serum, and therefore presumably
is due to delayed hypersensitivity.
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End ogenous Pyrogens
As mentioned previously polymorphonuclear leukocytes in
sterile saline-induced peritoneal exudates were first shown
by Beeson^® to release endogenous pyrogen®

Subsequent work by

several investigators 3ms shown that normal blood leukocytes,
both of rabbits®® and man,
pyrogen®

contain essentially no pre-formed

Leukocytes release pyrogen only in response to a number

of stimuli as previously described.

It had been thought for some

time that only granulocytic leukocytes were involved in the release
of endogenous pyrogen.

However, recently Atkins has demonstrated

that mononuclear macrophages which line the respiratory tree of
rabbits can be stimulated to release pyrogen by several agents.
Endogenous pyrogen is characterized by the rapidity of onset
of fever production when it is injected intravenously.

Unlike

other pyrogens that produce fever only after a variable period of
latency,

endogenous pyrogen produces an immediate, quickly rising

fever with a 5-10 minute lag.

Another characteristic is the failure

of an animal to develop significant tolerance to repeated injections
of endogenous pyrogen.
pyrogens*

ft

This is in distinct contrast to most exogenous

Atkins and Huang,

ft

however, described a very interesting

phenomenon that may be related to tolerance®

Large doses of leukocytic

pyrogen produce an immediate, biphasic fever with peaks at one and
three hours.

Repeated injections of such large doses leads to the

eventual disappearance of the second fever peak but never the first®
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Atkins believes that this may be explained as a direct action
on the thermoregulatory centers causing the first peak, while
the pyrogen causes the release of the recipient animal’s own
endogenous pyrogen to cause the second fever peak.

The mechanism

of partial tolerance seems to involve only the release of pyrogen
from the recipient’s cells.

1 1

Species specificity;
The question of species specificity has been raised with
regard to endogenous pyrogens, although little quantative data
is available,

Petersdorf and Bennett in 1957

124
' described their

experiments with sterile peritoneal exudates from dogs and rabbits.
The exudates contained pyrogens that were identical to previously
described leukocytic pyrogens in that they produced immediate fevers
in homologous animals.

Of note in their early experiments is that,

although the exudate pyrogen was quite active in the homologous
animal, it was entirely inactive in a heterologous system, i,e,9
rabbit pyrogen was not active in dogs, nor was canine pyrogen active
in rabbits.

Their conclusion was that species specificity might be

an important character of endogenous pyrogens*

Later experiments by

the same investigators show that canine serum endogenous pyrogen does
cause prompt monophasic fevers in rabbits®’’'^However, since they could
not demonstrate a dose-related response, they concluded again that
the pyrogens are species specific.

It would seem that this is not

necessarily the most logical conclusion from their experimental
results as published®
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More recently Bod el and Atkins

on

have shown that human blood

leukocytes, after incubation with endotoxin derived from Proteus
vulgaris or with heat«>killed Staphylococcus albus cells, release
a potent pyrogen that produces fever in rabbits and is distinct
from contaminating bacterial pyrogen*
Thus, the question, of species specificity is not resolved at
this time and awaits the outcome of more extensive experiments*
Naturally occuring pyrogens:
Soon after the discovery of granulocytic pyrogen, Bennett and
Beeson

1 7

reported on their efforts to find pyrogen occuring in

rabbit tissues other than leukocytes*

In short, they were unable

to find evidence of any pyrogenic material in extracts of normal
or inf arc ted kidney, spleen, heart or lung*

Likewise, no febrile

response could be elicited from extracts of erythrocytes, lymphocytes
or macrophages from peritoneal

exudates*

Extracts of acute inflam®

matory cutaneous Shwartsman and Arthus lesions produced fever when
injected intravenously*

The authors postulated that the large number

of polymorphonuclear leukocytes in these reactions could explain the
fevers observed*
Later, Snell and Atkins^® attempted again to demonstrate an
endogenous pyrogen in normal rabbit tissues, largely because there
are clinical and experimental fevers in which granulocytes do not
seem to be implicated*

Indeed, by using larger quantities of tissue

extracts than had been used before, they found that skeletal and
abdominal muscle, diaphragm, liver, kidney, heart, lung and spleen
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all yielded detectable pyrogen which in all but one case (kidney)
produced fevers much like granulocytic pyrogen.

These responses

were clearly shown not to be attributable to endotoxin contain"
inants and most unlikely due to sequestered granulocytes in the
homogenates.
Physico-chemical properties?
Because exact quantitation is difficult by the bioassay for
endogenous pyrogen, purification and biochemical characterization
has been quite difficult.

Rafter et. al.
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in 1960 described

some characteristics of the pyrogenic component of sterile rabbit
peritoneal exudates.

It was shown to be a non-dialyzable protein

which is precipitated by perchloric acid and extractable with phenol?
it is soluble in 50% methanol and 33% saturated, ammonium sulfate.
At that time they had achieved approximately 50-fold purification
by a combination of chemical and chromatographic techniques.

This

partially purified material contained less than 1% carbohydrate^
was resistant to periodate oxidation and was unaffected by butanol
extraction.

They also showed that this material contained at least

two components when tested by immunophoresis in Ouohterlony gel plates.
In some later studies, Hadley _et. al^,

described their pyrogen

obtained from serum of rabbits treated with intravenous Newcastle
Disease virus.

They achieved a 25-fold purification of the serum pyrogen

by successive acid and ethanol precipitations.

It was found to be

non-dialyzable and at least partially protein in nature in that it
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was destroyed by pepsin and trypsin*

It was extractable by phenol

but not by butanol and partially inactivated by periodate oxidation*
As can be seen, this virus-induced pyrogen has some characteristics
in common with Rafter9 s granulocytic pyrogen, but because of the
relatively crude preparations, no more exacting comparison can be
drawn®
Recently, Rafter et« al®

1 2ft

have reported on their further

modified technique of purification and some further characterization
of the leukocytic pyrogen,

it appears to be a lipo-protein complex

having a molecular weight between 109000 and 20,000 by sucrose
gradient centrifugation*

They offer several lines of evidence that

it contains an essential lipid components

(1) inactivation by cuprous

ions? (2) lability in solutions of pH 8*5 and aboves and (3) loss of
pyrogenicity after extraction with acid-isooctane*

Its solubility

in 66% methanol and the enhancing action of ethanol in freeing it
from sonicated cells are cited as evidence of the presence of exposed
lipid groups at its surface.

The authors believe that the demon¬

stration of an essential lipid component adds weight to the hypothesis
that leukocytic pyrogen is derived from cellular membranes.
Atkins has shown that protein synthesis is necessary for the
action of endogenous pyrogen®^

However, essentially nothing else is

known about its mechanism of action.

The site of action has been

presumed to be the brain since the response to intracarotid injection
is greater than to intravenous injection©94
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MATERIALS AND METHODS

1 nterf eron
Virus Strains?

A stock of a rabbit kidney cell-adapted

Sindbis virus (Egypt AR-339) was obtained by inoculation of
0*lec of a 10"1 dilution of the original stock onto 5-day
monolayer cultures of chick embryo fibroblasts.

The tissue

culture medium was harvested after 48 hours and made up to a
10# solution of bovine serum albumin.

The stock originally

titered to 10® TCID^q per ml. on tube cultures of primary
rabbit kidney cells.

The virus was stored in 1 ml. aliquots

at -70°C until used.
Vesicular stomatitis virus (Indiana) was prepared by inoculating 0.1 ml, of a 10

dilution of the original virus

suspension intracerebrally into suckling mice.

The mice brains

were harvested in 48 hours and homogenized in a solution of 10#
bovine serum albumin.

The virus was distributed into 1 ml.

aliquots and stored at -70°C until used.

The original titer of

the rims was 10® TCIDgQ per ml. on tube cultures of primary
rabbit kidney cells®
Tissue Culture Media? Two types of tissue culture media
were used*
H Hanks’

Growth Medium’*- Hanks’

salt solution base with 0.5#

lactaibumin hydrolysate, 5# fetal calf serum, phenol red indi¬
cator and approximately 200 units of penicillin and 200 p g of
streptomycin per ml.

Final pH 7.6-7,8.
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wfferle’s Maintenance Medium*- Earle’s salt solution base with 0»5%
lactalbuiriin hydrolysate, 5% calf serum, phenol red indicator and
approximately 200 units of penicillin and 200^ g of streptomycin
per ml.

Final pH 7.6-7.8*

Overlay medium- 0.5$ lactalbumin hydrolysate in Hanks'

balanced

salt solution, b% calf serum, sodium bicarbonate, 1,5% agar (Special
Agar-Noble, Difco Labs.), antibiotics, and neutral red (1*5$ of a
1i1000 solution per 100 ml.)
Primary rabbit kidney tissue cultures:

Two to 3 kg. white

New Zealand rabbits were killed by air embolism and the kidneys
were removed asceptically»

The capsules were removed and the kidneys

were washed in phosphate-buffered saline®

The cortices of the

kidneys were cut off and minced into small fragments.

The tissue

was transferred to a 125 ml, trypsinizing flask and 50 ml, of prewarmed 0»25%o trypsin (Flow Laboratories) in Earle's balanced, salt
solution was added to the flask.

The material was stirred at a

moderate speed by a magnetic stirrer for approximately 5 minutes#
The supernatant cell suspension was decanted into an Erlenmeyer
flask containing 50 ml. of chilled Hanks’
and kept cold.

balanced salts solution

The trypsinization was repeated until the kidney

tissue was exhausted; this usually required about 4-5 aliquots of
trypsin.
The cell suspension was then centrifuged in 200 ml, centrifuge
bottles at about 1000 RPM in an International FR2 centrifuge at 4°C,
The supernatant solution was decanted and the packed cells were
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resuspend ed in 50 ml. of Hanks’

growth medium.

The cell suspension

was filtered through 6 layers of sterile gauze and a cell count was
done on the .resulting suspension.

The cell concentration was ad”

justed to 4 X 10® cells per ml. and dispensed ( 1 ml. into 16 mm
culture tubes] 10 ml. into 3 oz. prescription bottles).
Three days after seeding, the original medium was replaced with
an equal volume of Hanks’
medium became acid.

growth medium.

This was done earlier if the

Monolayers were usually formed in 7 to 10 days

and were maintained until used with Earle’s maintenance medium.
Interference Assays: Two types of interference assays were
used, CPE«reduction in tube cultures and a plaque reduction method
in the prescription bottles.
(1) Tube cultures of primary rabbit kidney cells were prepared
as outlined above.

The solution to be tested for interferon activity

was freed of inducing virus in one of two ways.

The sample was heated

for 1 hour at 56°C and then centrifuged to removed precipitated matter
or it was dialyzed against 0.2 M KC1-HC1 buffer at pH 2.0 for 24 hours
at 4°C.

The pH was readjusted to 7.4 by re-dialyzing against Earle’s

balanced salts solution for an additional 12 hours.

These methods

have both been demonstrated to inactivate the viruses used but not
the interferon.®^The former was usually used because of its
simplicity and brevity.
Serial 2*»fold dilutions were made of the solution to be tested.
The maintenance medium was then decanted from the tube cultures and
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0*5 ml• of the tested material was added to each tube*

The material

was incubated at 37°C for 8 to 12 hours and then a challenging dose
of 1000 TCIDgQ of Sindbis virus in 1 ml. was added and allowed to
adsorb for 4 hours.

Assays were run in quadruplicate.

Controls

consisted of using 1 ml. of Erie’s maintenance medium instead of
the virus.

After the virus adsorption 1.0 ml. Earle’s maintenance

medium was added and the cultures were incubated at 37°C.

They

were checked at 12 hour intervals for the development of cytopathogenic effect, and the titer of interferon was considered to be the
highest dilution at which 50$ of the cultures showed inhibition of
CPF as interpolated by the Reed-Mueneh method.-^0Because the plaque reduction type of assay has been found to be
a more sensitive indicator of interferon activity than the CPE reduction method, it was also tested.

Confluent monolayers of the rabbit

kidney cells in 3 oz. prescription bottles were usually attained 10
days after seeding.

Here, too, 2-fold serial dilutions of the material

to be tested were made and o»5 ml. aliquots of the solution were
incubated at 37°C for 8 to 12 hours with the cell sheets.

A challenge

dose of 30-100 PFU of the Sindbis virus was added to each bottle and
allowed to adsorb for 4 hours.

The cultures were then overlaid with

plaquing medium and incubated upside down in a totally dark environ¬
ment.

The highest dilution of the test material which reduced the

number of plaques to 50$ of the inoculum as determined by controls
was to be considered to be the titer of interferon.

The plaquing

technique did not work, probably because the concentration of neutral
red was toxic for the cells
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End ogenous Pyrogen
General; Pyrogenicity assays were done in rabbits in order
to be able best to compare interferon and endogenous pyrogen in a
homologous system.
Male and female albino rabbits weighing 3-5 kg. were used
both as donors and recipients of materials to be assayed for
pyrogenicity.57

They were all caged individually in an air-

conditioned room and temperatures were recorded in an adjacent
room maintained at 65 to 70° F.
All glassware and needles were sterilized and made pyrogen™
free by dry heat at 170°C for 2 hours.

Commercial pyrogen-free

Cutter physiologic saline solution was used throughout.

All

materials were given to the rabbits intravenously by the marginal
ear veins.
Temperature recording;

Temperatures were recorded with rectal

thermistors with a Foxboro scanning switch fever recorder.

Rabbits

were restrained in metal or wooden stalls with openings for the head
and tail.

Before use, rabbits were trained by being restrained for

at least one 5 hour period.
an experiment.

They were not given food or water during

Only rabbits whose temperature did not exceed 40.5° C

and did not vary by more than o.3° C during the hour before injection
were used.

Temperatures were recorded every 15 minutes for the dur¬

ation of the experiment.

Some animals that had remained afebrile or

had rapidly regained a normal temperature were given a second dose
if they remained stable for at least 1 hour.
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EXPERX MENTAL AND DISCUSSION

It must be stated at the outset that a satisfactory series
of experiments were never completed to resolve the questions
originally posed®

However, an explanation of what was attempted

and why the experiments were not successful will be presented in
this section®
The general

experimental approach in assessing a possible

relationship between viral interference and endogenous pyrogen
was to compare these two phenomena in a single host system so
that any conclusions drawn would be unaffected by questions of
species specificity®

For this reason, and the fact that a well**

controlled pyrogen assay was readily available, the rabbit was
chosen as the source of host cells*

It was proposed to do recip¬

rocal experiments, i*e», to test material known to contain interferon
for its pyrogenicity and to test material shown to contain endogenous
pyrogen for its interfering properties®
Ho

describes a reliable assay using primary rabbit kidney

tissue cultures with vesicular stomatitis and Sindbis viruses as
inducing and assay virus, respectively®

It was thought that this

would be a suitable system to employ in investigating this problem®
Two major experiments were attempted;
(l) Monolayer cultures of the rabbit kidney cells in 3 oz» pre/?

scription bottles ( approximately 10° cells per bottle) were washed
twice with 10 cc of the pyrogen-free tissue culture medium*

They
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were then infected with 0.2 ml. of a 10”1 dilution of the VSV
stock which was allowed to adsorb for 30 minutes.

Ten ml. of the

pyrogen-free medium was added and the cultures were incubated at
37°C for 12 hours.

At that time about 50% of the cells were

observed to have detached from the glass in both uninoculated
control bottles and infected cultures.
specific cytopathogenic effect®

There was no sign of any

The medium was decanted and the

virus was h©at-imotivated as described earlier.

It was then

clarified by low-speed centrifugation and injected into rabbits
to test for pyrogenicity.

Both samples from uninfected controls

and infected cultures were found to elicit no febrile response
in the recipient rabbits.
When this material was assayed for interferon by the tube
dilution technique using Sindbis as a challenge virus, no inter®
ference was demonstrable.
(2) An attempt was made to assay material known to contain
endogenous pyrogen for virus interfering activity.

Rabbit alveolar

macrophages were suspended in a phosphate-buffered balanced salt
solution at pH 7.2.

They were incubated overnight at 37°C with

purified tuberculin protein.

The cellular material was removed by

centrifugation and the supernatant was demonstrated to cause an
immediate monoph&sie fever in rabbits.
Serial 2-fold dilutions were made of this supernatant and
0.5 ml. aliquots were added in replicates to tube cultures of the
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rabbit kidney cells after the medium was decanted*

These were then

incubated for 8 hours and then challenged with 1000 TCIDgg of the
VS virus (Indiana) in 0*1 ml*

The virus was allowed to adsorb for

30 minutes after which 1.0 ml* maintenance medium was added.

There

was no interference demonstrable during the ensuing 3 day period*
See Tabl el*

Table I*

Interferon Assay: CPE in rabbit kidney cell cultures
challenged with 1000 TCIDqq VSV (Indiana) read on
scale 1 to 4.

Material
assayed Control

---Undil®

1:5

1:10

1:20

1:40

1:80

!
..

i

8 hr

0

0

0

0

0

0

0

16 hr

0

0

0

0

0

0

0

24 hr

1

2

,,

o/i

1

2

1

48 hr

3

3

3

3

i

. .

3

3

3

3

Li

4

72 hr

4

4

|

4
L-—--

4

On many attempts, the major difficulty lay in trying to establish
a positive interferon assay*
the cell cultures themselves*

The first problem encountered was with
Early in the course of experimentation

the cells were found to grow quite slowly compared to other cell
systems and the shortest time in which monolayer cultures were achieved
was 10 days •

At this time, the cell layer was confluent but rather
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thin when compared to chick embryo fibroblast and rhesus monkey
kidney cultures of the same age*

Variations in types of media

and serum concentrations during the early growth phase of the
cultures were found to be ineffectual in achieving a more rapid
growth or heavier monolayers®
Another problem that was encountered early was that in order
to assay for endogenous pyrogen, any material tested by intravenous injection had to be free of any contaminating pyrogens,
either infectious or non-infectious»

Screening of a number of

commercially available tissue culture media showed that they
were invariably pyrogenic for rabbits# although sterile by culture*
The fever pattern produced was quite typical of an endotoxin-like
pyrogen and undoubtedly resulted from endotoxin contamination
during commercial preparation since all materials used in our
laboratories were pyrogen-free*
In an attempt to solve this problem, an Earle’s balanced
salts solution-base pyrogen-free tissue culture medium was pre¬
pared from basic ingredients that were demonstrated to be pyrogenfree*

This involved 2 hour autoclaving of components of the salts

solution separately ( as described by Hsiung^®) and similar treat¬
ment of Xactalbumin hydrolysate*
used in place of calf serum*

Pyrogen-free rabbit serum was

This type of medium was never found

to be satisfactory in that, although it was not pyrogenic, it was
incapable of maintaining the cell sheet for the time required for
interferon production*

After about 6 hours incubation in this medium.
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uninfected cells could be observed to be degenerating®

( An

explanation might be that the essential polypeptide and amino
acids in the lactalbumin hydrolysate were destroyed by the long
period of autoclaving.

)

A manner of eliminating the problem of pyrogenic tissue
culture media might be to use rabbits for the pyrogen assay that
have been made tolerant by repeated IV injections of endotoxins#
Rabbits treated this way have been shown to be unresponsive to
endotoxins but to remain responsive to endogenous pyrogens.

P

Other difficulties, loss of virus stocks and contaminations,
occurred before this could be attempted#
It is felt that because a positive assay for interferon was
never achieved, no valid conclusions could be drawn from these
two unsatisfactory experiments®

They could not be repeated because

of a very distressing gradual decline in the Sindbis virus titer,
even though the virus was stored at -70°C in 10% bovine serum
albumin®

Bacterial and fungal contaminants of the tissue cultures

also were perplexing problems®
In conclusion, the problem posed is a challenging one, but
probably soluble with some further refinement of experimental
design and technique®
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